Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 11/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.39 |
| ▸ | PLA2G2E | Q9NZK7 | 2/20 | 0.39 |
| ▸ | TSPO | P30536 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862534 | 0.91 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL27862241 | 0.91 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL818425 | 0.91 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6129641 | 0.90 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6129643 | 0.90 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6699097 | 0.89 | HTR6 (0.45) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL818490 | 0.88 | HTR6 (0.51) | HTR6PLA2G2APLA2G10TSPO | |
| SCHEMBL29863082 | 0.88 | HTR6 (0.51) | HTR6PLA2G2APLA2G10TSPO | |
| SCHEMBL2594431 | 0.88 | HTR6 (0.45) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6693682 | 0.87 | HTR6 (0.49) | HTR6PLA2G2APLA2G10TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | disclosed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-0839806-B1 | Substituted tricyclics | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | HTR6 3251/4885PLA2G2A 24/4885PLA2G10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.